Lonza Group AG
LONN
株式のランク
#447
Lonza Group AG, together with its subsidiaries, operates as a contract... Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
株価
$764.04
時価総額
$53.36B
変化（1日）
0.96%
変化（1年）
8.59%
国
CH
取引 Lonza Group AG (LONN)
カテゴリー
Healthcare
Lonza Group AG（LONN）の株式分割履歴
Lonza Group AG株（シンボル：LONN）は合計で0回の株式分割を実施しました。
最新の株式分割はOct 22, 2026に行われました。
Oct 22, 2026より前に購入されたLONN株は、現在0LONN株に相当します。
最新の株式分割はOct 22, 2026に行われました。
Oct 22, 2026より前に購入されたLONN株は、現在0LONN株に相当します。
株式分割一覧
| 年 | 株式分割 | 分割比率 | 累積分割比率 |
|---|---|---|---|
| 提供された日付のデータは十分ではありません。 | |||
類似企業または競合他社の株式分割
| 企業 | 株式分割の回数 | 累積分割比率 | 国 |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 1 | x100 |
BE
|
